Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

ExPEC: A Cause for Concern

Lilian Abbo Headshot
Lilian Abbo, MD, FIDSA
Program Director
person default
Julie Ann Justo, PharmD, MS
David Van Duin, MD, PhD, FIDSA, FAST
Released: November 3, 2022

Information on this Educational Activity

Program Director

Lilian Abbo, MD, FIDSA

Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida

Lilian Abbo, MD, FIDSA: consultant/advisor/speaker: Ferring.

Faculty

Julie Ann Justo, PharmD, MS

Clinical Associate Professor
Department of Clinical Pharmacy and Outcomes Sciences
University of South Carolina College of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
Department of Pharmacy
Prisma Health Richland Hospital
Columbia, South Carolina

Julie Ann Justo, PharmD, MS: consultant/advisor/speaker: bioMérieux,
Entasis Therapeutics, Gilead Sciences, Merck, Shionogi, Spero Therapeutics, Therapeutic Research Center; individual publicly traded stock/stock options: Vaxart.
David Van Duin, MD, PhD, FIDSA, FAST

Professor of Medicine
Director, 
Immunocompromised Host Infectious Diseases Program
Division of Infectious Diseases
University of North Carolina
Chapel Hill, North Carolina

David Van Duin, MD, PhD, FIDSA, FAST: consultant/advisor/speaker: Entasis, Merck, Pfizer, Qpex, Roche, Shionogi, Union; researcher: Merck, Shionogi.

Staff

Jacqueline Meredith, PharmD, BCIDP

Scientific Director

Jacqueline Meredith, PharmD, BCIDP, has no relevant financial relationships to disclose
Quentin Minson, PharmD

Director of Educational Strategy

Quentin Minson, PharmD, BCPS, BCIDP, has no relevant financial relationships to disclose
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant financial relationships to disclose
Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant financial relationships to disclose
Angeline Metilda, Mtech
Angeline Metilda, Mtech, has no relevant financial relationships to disclose
Swathi K

Editorial Contributor

Swathi.K, has no relevant financial relationships to disclose
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schultz, PhD, has no relevant financial relationships to disclose

Program Medium

This program has been made available online.

Related Content

Dr Emily Heil shares her approach to treating infections caused by KPC-producing bacteria, from Clinical Care Options (CCO)

Emily Heil, PharmD, MS, BCIDP, AAHIVP Released: January 3, 2023

Dr Dexter James Wiseman shares the latest data on RSV vaccines from IDWeek 2022, from Clinical Care Options (CCO)

Dexter James Wiseman, MD Released: December 29, 2022

Read about the latest updates on RSV vaccines from Dr Pamela Rockwell, from Clinical Care Options (CCO)

Pamela Rockwell, DO, FAAFP Released: December 23, 2022

Slideset providing an overview of the latest data on treating infections caused by gram-negative extensively drug-resistant organisms, from Clinical Care Options (CCO)

Released: December 16, 2022

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Therapeutics, Division of Janssen Products, LP

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings